tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Asymchem Laboratories Announces New Board Session and Director Appointment

Story Highlights
Asymchem Laboratories Announces New Board Session and Director Appointment

Elevate Your Investing Strategy:

Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ) has issued an update.

Asymchem Laboratories (Tianjin) Co., Ltd. announced the election of a new board session as the term of the fourth session concludes. The fifth session will include nine directors, with a mix of executive, non-executive, and independent non-executive directors. The board also proposed the appointment of Mr. Xie Weikai as an independent non-executive director, bringing extensive experience in equity financing and corporate governance to the company. This restructuring aims to strengthen the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (HK:6821) stock is a Hold with a HK$45.50 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.

More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H

Asymchem Laboratories (Tianjin) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, primarily engaged in the pharmaceutical industry. The company focuses on providing comprehensive services in drug development and manufacturing, catering to the needs of the global pharmaceutical market.

Average Trading Volume: 897,871

Technical Sentiment Signal: Buy

Current Market Cap: HK$36.12B

For detailed information about 6821 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1